Want to see AU:AHE full AI Analyst Report?
Top Page
MedAdvisor Limited
(Sydney:AHE)
Select Model
Select Model
Rating:39Underperform
Price Target:
AU$0.01
Action:Reiterated
Date:09/06/26
The score is driven primarily by very weak financial performance (persistent losses, negative equity, and recurring cash outflows) alongside a strongly bearish technical setup (price below all major moving averages and negative momentum indicators). Valuation provides limited support because the company is loss-making (negative P/E) and there is no dividend yield data.
Positive Factors
Connected healthcare technology platform
The company operates across a connected healthcare ecosystem rather than serving only one stakeholder group. Linking pharmacies, patients, and pharmaceutical brands can support multiple use cases and create a platform for recurring medication-management and engagement services over time.
Negative Factors
Persistent revenue deterioration
Repeated revenue declines indicate that the company has not established consistent top-line momentum. Continued contraction can weaken operating leverage, reduce the resources available for product investment, and make it harder to absorb fixed costs or convert the platform into sustainable growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Connected healthcare technology platform
The company operates across a connected healthcare ecosystem rather than serving only one stakeholder group. Linking pharmacies, patients, and pharmaceutical brands can support multiple use cases and create a platform for recurring medication-management and engagement services over time.
Read all positive factors
MedAdvisor Limited (AHE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$8.29M
Dividend YieldN/A
Average Volume (3M)379.36K
Price to Earnings (P/E)―
Beta (1Y)1.69
Revenue Growth-46.09%
EPS Growth70.70%
CountryAU
Employees3
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.03
Shares Outstanding637,981,000
10 Day Avg. Volume228,265
30 Day Avg. Volume379,356
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-3.12
Price to Sales (P/S)0.22
P/FCF Ratio-0.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$112.30M
MedAdvisor Limited Business Overview & Revenue Model
Company Description
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-drive...
How the Company Makes Money
null...
MedAdvisor Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 33.96M | 62.99M | 122.11M | 97.96M | 67.75M |
| Gross Profit | -3.49M | 3.97M | 23.63M | 12.59M | -1.84M |
| EBITDA | -16.53M | -11.93M | 7.05M | -3.03M | -11.29M |
| Net Income | -19.97M | -60.21M | 792.13K | -11.31M | -17.35M |
Balance Sheet | |||||
| Total Assets | 16.59M | 39.84M | 98.78M | 95.91M | 78.44M |
| Cash, Cash Equivalents and Short-Term Investments | 9.53M | 10.30M | 15.58M | 14.20M | 7.58M |
| Total Debt | 131.74K | 17.40M | 12.61M | 13.09M | 13.41M |
| Total Liabilities | 19.03M | 41.46M | 47.20M | 47.45M | 43.89M |
| Stockholders Equity | -2.44M | -1.62M | 51.58M | 48.46M | 34.55M |
Cash Flow | |||||
| Free Cash Flow | -10.27M | -14.37M | 3.35M | -1.63M | -548.13K |
| Operating Cash Flow | -10.27M | -14.37M | 5.19M | -1.45M | -236.32K |
| Investing Cash Flow | 9.92M | -2.18M | -2.80M | -3.23M | -290.79K |
| Financing Cash Flow | 284.23K | 11.34M | -831.97K | 12.42M | 1.86M |
MedAdvisor Limited Technical Analysis
―
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AHE, the sentiment is undefined. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for AU:AHE.
MedAdvisor Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$141.73M | 58.82 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$167.84M | -9.22 | -203.69% | ― | -1.53% | 28.29% | |
50 Neutral | AU$18.60M | ― | -578.72% | ― | 113.42% | 29.17% | |
44 Neutral | AU$58.62M | -34.40 | -14.09% | 6.52% | 4.06% | -625.00% | |
43 Neutral | AU$22.99M | -2.65 | -1688.04% | ― | 11.45% | 0.69% | |
39 Underperform | AU$8.29M | -0.42 | -614.15% | ― | -46.09% | 70.70% |
* Healthcare Sector Average
AU:AHE
MedAdvisor Limited
0.01
-0.04
-73.47%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.19
-0.04
-17.39%
AU:PHX
PharmX Technologies
0.09
-0.03
-28.33%
AU:ALC
Alcidion Group Limited
0.10
0.01
11.11%
AU:ICR
InteliCare Holdings Limited
0.03
<0.01
52.94%
AU:PCK
PainChek Ltd
0.12
-0.33
-73.86%
MedAdvisor Limited Corporate Events
Adheris Health Issues FY26 Results Presentation with Extensive Legal Disclaimers
Sep 1, 2026
Adheris Health released its FY26 results presentation, framing the document as general information rather than investment advice and emphasizing that it does not account for individual investor circumstances. The company stresses that the material...
Adheris Health appoints new CFO to support U.S. rebuild and profitability push
Aug 31, 2026
Adheris Health Limited has appointed Alison Hale as Chief Financial Officer, effective 1 September 2026, replacing outgoing CFO Sean Slattery. Hale brings experience from Deloitte and senior finance roles at the Linde Group and Elgas Limited, with...
Adheris Health Cuts Costs and Stabilises Cash Flow as Revenue Slides
Aug 31, 2026
Adheris Health reported FY26 revenue of A$34.0 million from continuing operations, down 46% year on year, with gross profit and margins also weaker amid lower customer renewals and reduced bookings in the prior pharma budget cycle. Statutory net l...
Adheris Health Completes Strategic Reset to Refocus on U.S. Growth
Aug 31, 2026
Adheris Health has completed a strategic reset over the year to 30 June 2026, upgrading its technology platform to deliver programs at scale and refreshing its executive leadership while recommitting to core customer relationships. The company has...
Adheris Health lodges ASX governance key and updates corporate oversight framework
Aug 30, 2026
Adheris Health Limited has lodged its Appendix 4G and related corporate governance disclosures for the year ended 30 June 2026 with the ASX. The company has elected to host its corporate governance statement on its website, confirming board approv...
Adheris Health Sets Date for FY26 Results and Investor Webinar
Aug 28, 2026
Adheris Health Limited, a healthcare technology company specializing in data-driven patient engagement and medication adherence solutions for pharmaceutical manufacturers, pharmacies, and healthcare providers, operates the THRiV platform to person...
Adheris Health Faces US Legal Action Over Terminated IT Services Deal
Jul 31, 2026
Adheris Health Limited has disclosed that its U.S. subsidiary, Adheris LLC, has been named as a defendant in legal proceedings brought by Mindsprint Pte. Ltd. in the United States District Court for the Southern District of New York. The dispute a...
Adheris Health Hits Cash-Flow Break-Even Despite Q4 Revenue Slump
Jul 22, 2026
Adheris Health reported a sharp year-on-year decline in fourth-quarter FY26 revenue to $5.6 million and gross profit to $2.0 million, as lingering effects from a challenging pharma budget cycle and weaker renewals weighed on results. Gross margin ...
Adheris Health Cuts Future Dilution as Lapsed Options Reduce Capital Overhang
Jul 10, 2026
Adheris Health Limited, traded on the ASX under the ticker AHE, is a healthcare-focused company that appears to centre its operations on adherence-related health services, utilising option-based incentive schemes within its broader capital managem...
Adheris Health Seeks ASX Quotation for New Share Issue
Jul 8, 2026
Adheris Health Limited has applied to the ASX for quotation of 304,200 new ordinary fully paid shares, issued on June 2, 2026. The application formalizes the listing of these securities following their creation through the exercise or conversion o...
Adheris Health Appoints John Murray to Board with No Initial Securities Interest
Jul 1, 2026
Adheris Health Limited has appointed John Murray as a director effective 1 July 2026, according to an initial director’s interest notice lodged with the ASX. The filing confirms that Murray holds no relevant interests in the company’s ...
Adheris Health Director Sean Slattery Steps Down with No Ongoing Equity Interest
Jul 1, 2026
Adheris Health Limited has announced the departure of director Sean Slattery, who ceased to be a director of the company on 1 July 2026. The company reported that Slattery holds no relevant interests in Adheris Health securities, either directly, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.